SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.69 | $0 | -$14M |
| 2025 Q4 | -0.38 | $0 | -$10M |